

**Anti-ICOS / CD278 Reference Antibody (vopratelimab)  
Recombinant Antibody  
Catalog # APR10287**

**Specification**

---

**Anti-ICOS / CD278 Reference Antibody (vopratelimab) - Product Information**

Application	FC, E, FTA
Primary Accession	<a href="#">O9Y6W8</a>
Reactivity	Cynomolgus, Human, Mouse
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	145.8 KDa

**Anti-ICOS / CD278 Reference Antibody (vopratelimab) - Additional Information**

**Target/Specificity**  
ICOS / CD278

**Endotoxin**  
< 0.001EU/ µg,determined by LAL method.

**Conjugation**  
Unconjugated

**Expression system**  
CHO Cell

**Format**  
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

**Anti-ICOS / CD278 Reference Antibody (vopratelimab) - Protein Information**

**Name** ICOS

**Synonyms** AILIM

**Function**  
Stimulatory receptor expressed in activated or antigen- experienced T-cells that plays an important role in the immune response (PubMed:<a href="http://www.uniprot.org/citations/9930702" target="\_blank">9930702</a>). Upon binding to its ligand ICOSL expressed on antigen presenting cells (APCs), delivers costimulatory signals that enhances all basic T-cell responses to a foreign antigen, namely proliferation, secretion of lymphokines including IL10, up-regulation of molecules that mediate cell-cell interaction, and effective help for antibody secretion by B-cells (PubMed:<a href="http://www.uniprot.org/citations/33033255" target="\_blank">33033255</a>). Acts also as a costimulatory receptor critical for the differentiation of T follicular regulatory cells upon immune challenges such as viral infection (PubMed:<a href="http://www.uniprot.org/citations/27135603" target="\_blank">27135603</a>).

target="\_blank">27135603</a>). Mechanistically, potentiates TCR-induced calcium flux by augmenting PLCG1 activation and actin remodeling (By similarity). In addition, activates PI3K signaling pathways independently of calcium flux (PubMed:<a href="http://www.uniprot.org/citations/30523347" target="\_blank">30523347</a>). Essential both for efficient interaction between T and B-cells and for normal antibody responses to T-cell dependent antigens. Prevents the apoptosis of pre-activated T-cells. Plays a critical role in CD40-mediated class switching of immunoglobulin isotypes (By similarity).

#### Cellular Location

[Isoform 1]: Cell membrane; Single-pass type I membrane protein

#### Tissue Location


Activated T-cells. Highly expressed on tonsillar T- cells, which are closely associated with B-cells in the apical light zone of germinal centers, the site of terminal B-cell maturation Expressed at lower levels in thymus, lung, lymph node and peripheral blood leukocytes. Expressed in the medulla of fetal and newborn thymus

### Anti-ICOS / CD278 Reference Antibody (vopratelimab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

### Anti-ICOS / CD278 Reference Antibody (vopratelimab) - Images



Anti-ICOS / CD278 Reference Antibody (vopratelimab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-ICOS / CD278 Reference Antibody (vopratelimab) is more than 99.09% ,determined by SEC-HPLC.